Company
Every investor coverage indicates participated in a round Imugene raised.
Companies Imugene acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Bradley Glover | Chief Operating Officer | @AuManufacturing |
| Leslie Chong | MD and CEO | @AuManufacturing, Brandon Capital portfolio |
| Paul Hopper | Executive Chairman | @AuManufacturing |
Stories naming Imugene. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of manufacturing briefs: biotech Imugene's share plan added A$18.2 million, EVOS shifted its Brisbane head office, ANSTO won federal backing for nuclear medicine, CSIRO endowed Wollongong scholarships, plus two chief executive appointments.
Manufacturing briefs: XRF Scientific posts record results, Universal Biosensors receives an R&D tax rebate, Imugene and SMC appoint executives, FWPA promotes forestry in a new campaign, and AGL agrees a Loy Yang transition fund.
Sydney clinical trials platform HealthMatch raised a $10 million Series C led by Folklore Ventures with Square Peg participating, after laying off half its staff in June; funds will support rehiring and US expansion.
Also SmartCompany·Techboard
Manufacturing roundup: Amaero appoints Guggenheim to review strategy, Cann completes its Mildura facility, ADN lines up a $4.5m placement, Imugene starts an MSD cancer trial, ABT collects an R&D tax refund.
Melbourne cancer immunotherapy startup Currus Biologics, spun out of Peter MacCallum, raised $10 million led by the Brandon Capital-managed Medical Research Commercialisation Fund with Uniseed, to advance its BEAT technology toward human trials.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·SmartCompany·Startup Daily·SmartCompany·Startup Daily